Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a...

Viatris Inc. Common Stock (VTRS) has a valuation score of 75/100 (strong), profitability score of 24/100 (weak), financial health score of 33/100 (weak), Piotroski F-Score of 5/9, Altman Z-Score of 0.73 (distressed), revenue growth of -4.2% YoY.

Neutral

Analyst Consensus

Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations17 analysts · 2026-08-01
4
7
5
Strong Buy 4Buy 7Hold 5Sell 1Strong Sell 0

Recent Market Moves

See all VTRS moves →
DateSessionPriceMoveZ-Score
Aug 7Pre-market$16.29-6.69%-4.46
Aug 6Regular$16.59-6.03%-4.02
Aug 6After-hours$16.47-6.69%-4.46
Aug 3Pre-market$17.56-3.35%-2.24
Viatris Inc. Common Stock (VTRS) Valuation & P/E History →Viatris Inc. Common Stock (VTRS) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →